Committed to the Future of Antibiotics
News
22 August 2018
Presenting Research at ACG 2018 on Quality of Life of Patients with Clostridium difficile
The Da Volterra team is thrilled to present a poster at the (...)
17 August 2018
Da Volterra receives new patent for innovative DAV132
The US Patent and Trademark Office has recently granted a new (...)
8 August 2018
Da Volterra Pleased to Sponsor the 6th International C. difficile Symposium September 12-14th
Da Volterra is pleased to be a sponsor of the 6th International (...)
20 July 2018
Tune-in July 24th to C. Diff Spores and More Radio Show to Learn About DAV132 with Our CSO
Da Volterra is looking forward to being on air with the C. Diff (...)
Who we are
Da Volterra:
Committed to the Future of Antibiotics
Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.
Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:
DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >